Voxelotor
Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that covalently and reversibly binds to the alpha-chain of hemoglobin, increasing hemoglobin oxygen affinity and stabilizing the oxygenated state to prevent HbS sickling and polymer formation in red blood cells. It is approved for sickle cell disease in patients aged 4 years and older to increase hemoglobin levels and reduce hemolysis. By preventing red blood cell sickling, it improves anemia and reduces vaso-occlusive complications.
الوزن الجزيئي
337,4000 g/mol
LogP
2,70
TPSA
77,20 Ų
قاعدة ليبينسكي للخمسة
ناجح
Pharmacokinetics (PK)
Pharmacodynamics (PD)
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O
InChI
InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
Molecular Formula
C19H19N3O3
HBD / HBA
1 / 5
الروابط القابلة للدوران
6
الذرات الثقيلة
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that covalently and reversibly binds to the alpha-chain of hemoglobin, increasing hemoglobin oxygen affinity and stabilizing the oxygenated state to prevent HbS sickling and polymer formation in red blood cells. It is approved for sickle cell disease in patients aged 4 years and older to increase hemoglobin levels and reduce hemolysis. By preventing red blood cell sickling, it improves anemia and reduces vaso-occlusive complications.
Yes, Voxelotor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4101807. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71602803. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="voxelotor"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/voxelotor/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/voxelotor/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/voxelotor/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="voxelotor"></drugfyi-drug>